ANI's Q2 revenue beat but Cortrophin guidance cut and legal loss weigh
Record Q2 revenue and $100M buyback ANI reported record Q2 2026 revenue of $266 million, up 25.9% from a year ago, and adjusted earnings per share of $2.21 beat expectations. The board also authorized a $100 million share buyback through 2029, which supports the stock by returning cash to shareholders.
This is the core positive financial result that drove the quarter and shows the company's underlying growth.
Cortrophin guidance cut despite volume growth ANI lowered its 2026 Cortrophin Gel revenue outlook to $520-$540 million from $540-$575 million, and Q2 Cortrophin sales of $117.1 million missed the $120.4 million consensus. This signals weaker-than-expected demand for a key drug and pressures the stock.
The guidance cut is the main negative event of the period and directly explains why the stock fell after earnings.
Full-year guidance misses, stock drops 9.1% Even though Q2 revenue beat estimates by 2.4%, ANI's full-year revenue guidance slightly missed expectations, making it the weakest guidance among four generic drug peers. The stock fell 9.1% to $75.12, reflecting investor disappointment with the forward outlook.
This captures the market reaction and the relative weakness versus peers, which is central to why the stock moved.
Legal setback in CG Oncology royalty dispute A Delaware court denied ANI's motions for a new trial and judgment in its dispute with CG Oncology over a 5% royalty on future sales of cretostimogene grenadenorepvec. ANI will appeal to the Delaware Supreme Court, but the loss threatens a potential royalty revenue stream and adds uncertainty.
This is a distinct negative legal development that could affect future royalty income and investor sentiment.